These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16740697)

  • 21. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms.
    Lin MC; Burkholder KA; Viswanathan AN; Neuberg D; Mutter GL
    Cancer; 2009 May; 115(10):2111-8. PubMed ID: 19280590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
    Monte NM; Webster KA; Neuberg D; Dressler GR; Mutter GL
    Cancer Res; 2010 Aug; 70(15):6225-32. PubMed ID: 20631067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.
    Mutter GL; Monte NM; Neuberg D; Ferenczy A; Eng C
    Cancer Res; 2014 May; 74(10):2796-802. PubMed ID: 24662919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities.
    Pallares J; Bussaglia E; Martínez-Guitarte JL; Dolcet X; Llobet D; Rue M; Sanchez-Verde L; Palacios J; Prat J; Matias-Guiu X
    Mod Pathol; 2005 May; 18(5):719-27. PubMed ID: 15578076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involution of PTEN-null endometrial glands with progestin therapy.
    Zheng W; Baker HE; Mutter GL
    Gynecol Oncol; 2004 Mar; 92(3):1008-13. PubMed ID: 14984979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Arnes M; Straume B; Maltau JM; Ørbo A
    Gynecol Oncol; 2003 Dec; 91(3):526-33. PubMed ID: 14675671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
    Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
    Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrauterine progesterone treatment of early endometrial cancer.
    Montz FJ; Bristow RE; Bovicelli A; Tomacruz R; Kurman RJ
    Am J Obstet Gynecol; 2002 Apr; 186(4):651-7. PubMed ID: 11967486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pten, a protean tumor suppressor.
    Mutter GL
    Am J Pathol; 2001 Jun; 158(6):1895-8. PubMed ID: 11395362
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular identification of latent precancers in histologically normal endometrium.
    Mutter GL; Ince TA; Baak JP; Kust GA; Zhou XP; Eng C
    Cancer Res; 2001 Jun; 61(11):4311-4. PubMed ID: 11389050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
    Stambolic V; Tsao MS; Macpherson D; Suzuki A; Chapman WB; Mak TW
    Cancer Res; 2000 Jul; 60(13):3605-11. PubMed ID: 10910075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in endometrial PTEN expression throughout the human menstrual cycle.
    Mutter GL; Lin MC; Fitzgerald JT; Kum JB; Eng C
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2334-8. PubMed ID: 10852473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
    Mutter GL; Lin MC; Fitzgerald JT; Kum JB; Baak JP; Lees JA; Weng LP; Eng C
    J Natl Cancer Inst; 2000 Jun; 92(11):924-30. PubMed ID: 10841828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors.
    Gimm O; Perren A; Weng LP; Marsh DJ; Yeh JJ; Ziebold U; Gil E; Hinze R; Delbridge L; Lees JA; Mutter GL; Robinson BG; Komminoth P; Dralle H; Eng C
    Am J Pathol; 2000 May; 156(5):1693-700. PubMed ID: 10793080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
    Perren A; Weng LP; Boag AH; Ziebold U; Thakore K; Dahia PL; Komminoth P; Lees JA; Mulligan LM; Mutter GL; Eng C
    Am J Pathol; 1999 Oct; 155(4):1253-60. PubMed ID: 10514407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of oral contraceptives and endometrial cancer risk (Sweden).
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Lindgren A; Persson I
    Cancer Causes Control; 1999 Aug; 10(4):277-84. PubMed ID: 10482486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mutation rate and cancer.
    Jackson AL; Loeb LA
    Genetics; 1998 Apr; 148(4):1483-90. PubMed ID: 9560368
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.